PMID- 35001410
OWN - NLM
STAT- MEDLINE
DCOM- 20220615
LR  - 20220626
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
VI  - 88
IP  - 7
DP  - 2022 Jul
TI  - The effects of saffron (Crocus sativus L.) in conjunction with concurrent 
      training on body composition, glycaemic status, and inflammatory markers in obese 
      men with type 2 diabetes mellitus: A randomized double-blind clinical trial.
PG  - 3256-3271
LID - 10.1111/bcp.15222 [doi]
AB  - AIMS: Chronic inflammation is one of the major challenges in the management of 
      obesity and type 2 diabetes mellitus (T2DM). Our primary aim was to assess the 
      anti-inflammatory effects of Saffron (Crocus sativus L.) supplementation and 
      concurrent training in obese men with T2DM. METHODS: Sixty obese men with T2DM 
      (age = 39 +/- 5 years; body mass = 93.9 +/- 6 kg) were randomly assigned to four 
      groups; concurrent training + placebo (CT; n = 15), saffron supplementation (S; 
      n = 15), concurrent training + saffron supplementation (CTS; n = 15), or control 
      (CON; n = 15). The participants in the CT group performed concurrent training 
      (resistance + aerobic) three times per week for 12 weeks and received daily one 
      pill of placebo (maltodextrin); the participants in the S group supplemented with 
      one pill of 100 mg of saffron daily, and the participants in the CTS group 
      participated in both saffron and training intervention while CON group continued 
      regular lifestyle (no training and no supplementation). Inflammatory markers, 
      body composition (evaluated by a multi-frequency bioelectrical impedance device; 
      Jawon X-Contact 356), and metabolic profile were evaluated before and after 
      interventions. RESULTS: All three interventions significantly (P < .05) decreased 
      TNF-alpha (CT = -4.22, S = -1.91, CTS = -9.69 pg/mL), hs-CRP (CT = -0.13, S = -0.1, 
      CTS = -0.32 ng/mL), IL-6 (CT = -6.84, S = -6.36, CTS = -13.55 pg/mL), IL-1beta 
      (CT = -8.85, S = -6.46, CTS = -19.8 pg/mL), FBG (CT = -6.97, S = -2.45, 
      CTS = -13.86 mg/dL), insulin (CT = -0.13, S = -0.03, CTS = -0.21 mU/L), HOMA-IR 
      (CT = -0.12, S = -0.04, CTS = -0.21), HbA1c (CT = -0.17, S = -0.11, 
      CTS = -0.26%), and increased IL-10 (CT = 1.09, S = 0.53, CTS = 2.27 pg/mL) 
      concentrations. There was a positive correlation between changes in BFP with 
      hs-CRP, IL-6, IL-1beta and TNF-alpha, and IL-10 concentrations across the intervention 
      groups. Additionally, significant differences were observed between the changes 
      for all variables in the CTS group compared to CT, S and CON groups (P < .05). 
      CONCLUSION: It seems that an interaction of saffron supplementation and 
      concurrent training has more efficient effects on anti-inflammatory status 
      compared to saffron supplementation or concurrent training alone.
CI  - (c) 2022 British Pharmacological Society.
FAU - Hooshmand Moghadam, Babak
AU  - Hooshmand Moghadam B
AUID- ORCID: 0000-0002-2036-9492
AD  - Department of Exercise Physiology, Ferdowsi University of Mashhad, Mashhad, Iran.
FAU - Rashidlamir, Amir
AU  - Rashidlamir A
AUID- ORCID: 0000-0001-6180-8554
AD  - Department of Exercise Physiology, Ferdowsi University of Mashhad, Mashhad, Iran.
FAU - Attarzadeh Hosseini, Seyyed Reza
AU  - Attarzadeh Hosseini SR
AD  - Department of Exercise Physiology, Ferdowsi University of Mashhad, Mashhad, Iran.
FAU - Gaeini, Abbas Ali
AU  - Gaeini AA
AD  - Department of Exercise Physiology, University of Tehran, Tehran, Iran.
FAU - Kaviani, Mojtaba
AU  - Kaviani M
AD  - School of Nutrition and Dietetics, Acadia University, Wolfville, Nova Scotia, 
      Canada.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20220218
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Interleukin-6)
RN  - 0 (Plant Extracts)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 130068-27-8 (Interleukin-10)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents
MH  - Biomarkers
MH  - Body Composition
MH  - C-Reactive Protein
MH  - *Crocus
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Double-Blind Method
MH  - Humans
MH  - Interleukin-10
MH  - Interleukin-6
MH  - Male
MH  - Obesity/complications/drug therapy
MH  - Plant Extracts/pharmacology/therapeutic use
MH  - Tumor Necrosis Factor-alpha
OTO - NOTNLM
OT  - Crocus sativus
OT  - diabetes mellitus
OT  - inflammation
OT  - obesity
OT  - physical exercise training
EDAT- 2022/01/11 06:00
MHDA- 2022/06/16 06:00
CRDT- 2022/01/10 06:34
PHST- 2021/11/09 00:00 [revised]
PHST- 2021/10/21 00:00 [received]
PHST- 2021/12/05 00:00 [accepted]
PHST- 2022/01/11 06:00 [pubmed]
PHST- 2022/06/16 06:00 [medline]
PHST- 2022/01/10 06:34 [entrez]
AID - 10.1111/bcp.15222 [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2022 Jul;88(7):3256-3271. doi: 10.1111/bcp.15222. Epub 2022 
      Feb 18.